Avenue Therapeutics (ATXI)
(Delayed Data from NSDQ)
$2.61 USD
-0.09 (-3.33%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $2.62 +0.01 (0.38%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Avenue Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 15 | 8 | 4 | 5 | 26 |
Income After Depreciation & Amortization | -15 | -8 | -4 | -5 | -26 |
Non-Operating Income | 4 | 4 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -10 | -4 | -4 | -5 | -26 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | -4 | -4 | -5 | -26 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | -4 | -4 | -5 | -26 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -15 | -8 | -4 | -5 | -26 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -15 | -8 | -4 | -5 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.14 | 0.03 | 0.02 | 0.02 | 0.01 |
Diluted EPS Before Non-Recurring Items | -73.68 | -122.56 | -248.00 | -349.45 | -1,859.97 |
Diluted Net EPS (GAAP) | -73.68 | -122.56 | -248.00 | -349.45 | -1,859.97 |
Fiscal Year end for Avenue Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 2.82 | 3.71 | 2.12 | 2.07 | 3.93 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.82 | -3.71 | -2.12 | -2.07 | -3.93 |
Non-Operating Income | 0.12 | -0.64 | 2.74 | 2.58 | -0.09 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.70 | -4.35 | 0.62 | 0.51 | -4.02 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.70 | -4.35 | 0.62 | 0.51 | -4.02 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.69 | -4.34 | 0.64 | 0.53 | -4.01 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1.12 | 0.56 | 0.02 | 0.11 | 0.10 |
Diluted EPS Before Non-Recurring Items | -6.43 | -15.40 | 42.11 | 4.51 | -39.10 |
Diluted Net EPS (GAAP) | -6.43 | -15.40 | 62.41 | 4.51 | -39.10 |